Karyopharm Therapeutics (KPTI) Long-Term Deferred Tax (2017)

Karyopharm Therapeutics' (KPTI) quarterly Long-Term Deferred Tax came in at $1.8 million in Q1 2017.

Karyopharm Therapeutics (KPTI) Long-Term Deferred Tax (2017) Analysis & Trends

Karyopharm Therapeutics (KPTI) has 1 years of Long-Term Deferred Tax data on file, last reported at $1.8 million in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Karyopharm Therapeutics	56.72 Mn	56.72 Mn	32.35 Mn

Download Data

Date	Value
Mar 31, 2017	1.84 Mn